Nexipox Plus

Nexipox Vaccine Overview

 Introduction

Nexipox Plus® represents the latest advancement in Varicella (Chickenpox) immunization, specifically engineered to meet the unique clinical and environmental challenges of the Indian healthcare landscape.

The Nexipox vaccine is a Live Attenuated vaccine designed to protect against the varicella zoster virus OKA strain (>2000 PFU), which causes chickenpox. It helps the immune system recognize and fight the virus. The virus responsible for causing chickenpox. This strain was originally isolated from a child with natural varicella and has been attenuated through laboratory processes to make it safe for use in vaccination.

Key Innovation: The 2X Trehalose System

The primary clinical advancement of Nexipox Plus® is its specialized formulation, designed for superior stability in tropical climates:

• 2X Trehalose-Based Stabilizer: Replaces traditional stabilizers like gelatin and mannitol. This patented system enhances viral stability and ensures potency retention even under variable cold-chain conditions.

• Gelatin-Free Formulation: By removing gelatin, the vaccine significantly reduces the risk of allergic reactions and antigen crystallization, ensuring a higher safety profile and improved tolerability for patients.

• Enhanced Immunogenicity: Clinical trials in Indian patients demonstrated a 98% seroconversion rate following a two-dose schedule, with a 35.4-fold rise in antibody titers.

Regulatory Status & Indications

• DCGI Approval: Approved by the Drugs Controller General of India (DCGI) for active immunization against Varicella in individuals from 12 months of age and older.

Global Reach: Built on technology patented across 156 countries, reflecting world-class manufacturing standards. 

Benefits

•  Effective Protection: Provides immunity against chickenpox.
•  Rapid Immunization: Quick onset of immunity after vaccination.
•  Safe and Tested: Thoroughly tested for safety and efficacy.

 Dosage and Administration

•  Schedule: Typically administered in two doses > 12 month age- 12 yr,2 doses-3 month apart.> 12 yr-2 doses 4-8 wk apart.
•  Method: Subcutaneous injection- deltoid or anterolateral thigh.

 Side Effects

• Common side effects may include mild rash, soreness at the injection site, and mild fever. Severe reactions are rare but should be reported to a healthcare provider.

 Recommendations

•  Suitable for children over 12 months and susceptible adults.
•  Consult a healthcare professional if you have any health conditions before administration.

    Indications for Pregnancy and Lactation

• Pregnancy: Not recommended during pregnancy. Women should avoid getting pregnant for at least three months after receiving the vaccine.
• Lactation: Generally considered safe, but consult with a healthcare provider for personalized advice.

   ContraIndications:

• Hypersensitivity
• Serious disease- acute / chronic infection, fever, advanced immune disease (TLC <1200 or cellular immunodeficiency, congenital immune disease) 
• Patients on steroids, leukemia

 Storage

•  Keep refrigerated at +2 to +8°C.
•  Do not freeze.

 Conclusion

• The Nexipox vaccine is a reliable and efficient solution for preventing chickenpox, contributing to public health safety. Always consult with healthcare providers for personalized medical advice

  Manufacturer & Distribution

  • Production: Manufactured by Changchun BCHT Biotechnology Co., China, a global leader in live attenuated vaccine technology.

  • License & Marketing: Imported under official license and marketed by Novo Medi Sciences Pvt. Ltd. (Novo Group), an Indian pharmaceutical legacy with over 80 years of expertise in niche biologicals.